Naphazoline/pheniramine
| Combination of | |
|---|---|
| Naphazoline | Vasoconstrictor |
| Pheniramine | Antihistamine |
| Clinical data | |
| Trade names | Naphcon-A, Opcon-A, Visine-A, others |
| AHFS/Drugs.com | Multum Consumer Information |
| Routes of administration | Eye drop |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
Naphazoline/pheniramine, sold under the brand name Naphcon-A among others, is a combination eye drop used to help the symptoms of allergic conjunctivitis such as from hay fever.[2] It contains naphazoline and pheniramine.[2][1] It is used as an eye drop.[1] Use is not recommended for more than three days.[3]
Side effects may include allergic reactions, eye pain, and dilated pupils.[2][4][3] It is unclear if use in pregnancy is safe.[1] Nephazoline works by resulting in constriction of blood vessels thus decreasing redness while pheniramine works by blocking the effects of histamine to stop itching.[1]
The combination was approved for medical use in the United States in 1994.[5][6][1] It is available over the counter.[5][6][2] In 2017, it was the 203rd most commonly prescribed medication in the United States, with more than two million prescriptions.[7][6]
- ^ a b c d e f "Naphazoline and pheniramine ophthalmic Uses, Side Effects & Warnings". Drugs.com. Retrieved 19 April 2019.
- ^ a b c d "Naphcon A- naphazoline hydrochloride and pheniramine maleate solution/ drops". DailyMed. 16 September 2019. Retrieved 10 August 2020.
- ^ a b Kizior RJ, Hodgson BB (2014). Saunders Nursing Drug Handbook 2015 - E-Book. Elsevier Health Sciences. p. 163. ISBN 9780323280181.
- ^ "Naphazoline/pheniramine ophthalmic Side Effects in Detail". Drugs.com. Retrieved 19 April 2019.
- ^ a b "Naphcon-A: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on April 30, 2017. Retrieved 19 April 2020.
- ^ a b c "Naphazoline Hydrochloride; Pheniramine Maleate - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.